| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.12.25 | Predictmedix AI Inc: Predictmedix AI looks back at 2025 | 4 | Stockwatch | ||
| PREDICTMEDIX AI Aktie jetzt für 0€ handeln | |||||
| 17.12.25 | Predictmedix AI Inc.: Predictmedix AI Inc - 2025 Year End Corporate Update | 230 | Newsfile | Toronto, Ontario--(Newsfile Corp. - December 17, 2025) - Predictmedix AI Inc. (CSE: PMED) (OTC Pink: PMEDF) (FSE: 3QP0) ("Predictmedix" or the "Company") concludes 2025 having delivered a year of... ► Artikel lesen | |
| 06.12.25 | Predictmedix AI Inc: Predictmedix AI closes final tranche of financing | 5 | Stockwatch | ||
| 05.12.25 | Predictmedix AI Inc.: Predictmedix AI Announces Closing of Final Tranche of Non-Brokered Private Placement | 420 | Newsfile | Toronto, Ontario--(Newsfile Corp. - December 5, 2025) - Predictmedix AI Inc. (CSE: PMED) (OTC Pink: PMEDF) (FSE: 3QP0) ("Predictmedix" or the "Company"), an emerging leader in AI-powered health and... ► Artikel lesen | |
| 18.11.25 | Predictmedix AI Inc: Predictmedix AI closes first tranche of financing | 20 | Stockwatch | ||
| 17.11.25 | Predictmedix AI Inc.: Predictmedix AI Announces Closing of $460,150 First Tranche | 488 | Newsfile | Toronto, Ontario--(Newsfile Corp. - November 17, 2025) - Predictmedix AI Inc. (CSE: PMED) (OTC Pink: PMEDF) (FSE: 3QP0) ("Predictmedix" or the "Company"), an emerging leader in AI-powered health and... ► Artikel lesen | |
| 20.10.25 | Predictmedix AI Inc: Predictmedix AI arranges $900,000 private placement | 3 | Stockwatch | ||
| 20.10.25 | Predictmedix AI Inc.: Predictmedix AI Announces Non-Brokered Private Placement | 352 | Newsfile | Toronto, Ontario--(Newsfile Corp. - October 20, 2025) - Predictmedix AI Inc. (CSE: PMED) (OTC Pink: PMEDF) (FSE: 3QP0) ("Predictmedix" or the "Company"), an emerging leader in AI-powered health and... ► Artikel lesen | |
| 01.10.25 | Predictmedix AI Inc: Predictmedix launches clinical trial AI platform | 1 | Stockwatch | ||
| 01.10.25 | Predictmedix AI bringt KI-Plattform der nächsten Generation für klinische Studien auf den Markt | 611 | IR-WORLD | Adaptives "digitales Gehirn" soll Risiken, Kosten und Zeitaufwand im 70-Mrd.-$-schweren Markt für klinische Studien
reduzieren1
Toronto, 1. Oktober 2025 / IRW-Press / Predictmedix... ► Artikel lesen | |
| 01.10.25 | Predictmedix AI Inc.: Predictmedix AI Launches Next-Generation Clinical-Trial AI Platform | 452 | Newsfile | Adaptive "digital brain" designed to cut risk, cost and timelines in the $70-billion clinical-trials market1Toronto, Ontario--(Newsfile Corp. - October 1, 2025) - Predictmedix AI Inc. (CSE: PMED) (OTC... ► Artikel lesen | |
| 29.09.25 | Predictmedix AI Inc.: Predictmedix AI to Present at the 25th MK Investment Conference in Munich, Germany | 454 | Business Wire | Predictmedix AI Inc. (CSE: PMED) (OTC: PMEDF) (FRA: 3QP0) ("Predictmedix" or the "Company"), an emerging leader in AI-powered health and safety technology, is pleased to announce that its Chief Operating... ► Artikel lesen | |
| 24.09.25 | Predictmedix AI Inc: Predictmedix AI talks up "multivertical" growth plan | 1 | Stockwatch | ||
| 24.09.25 | Predictmedix AI lanciert multivertikale Wachstumsstrategie, um sich als Marktführer im Bereich der KI-gestützten Gesundheitstechnologien zu positionieren | 391 | IR-WORLD | Klinisch validierte KI-Stationen dienen als Fundament für den Ausbau der Aktivitäten in den Bereichen Optimierung klinischer
Studien und digitale Gesundheit für Konsumenten. Daraus ergeben sich... ► Artikel lesen | |
| 02.07.25 | Predictmedix AI expandiert in die mobile Diagnostik mit neuer KI-gesteuerter Diabetes-Screening-Plattform | 472 | IR-WORLD | TORONTO, 2. Juli 2025 / IRW-Press / Predictmedix AI Inc. (CSE: PMED | OTC: PMEDF | FWB: 3QP), ein führender Anbieter von Vorsorgelösungen für Künstliche
Intelligenz, expandiert mit einer mobilen... ► Artikel lesen | |
| 08.05.25 | Predictmedix AI Inc.: Predictmedix AI to Headline Exclusive European Investor Roadshow Across Budapest, Zagreb, and Belgrade | 595 | Business Wire | Predictmedix AI Inc. (CSE: PMED) (OTC: PMEDF) (FRA: 3QP) ("Predictmedix" or the "Company"), a leading provider in AI-driven health and safety solutions, is proud to announce its participation as one... ► Artikel lesen | |
| 11.04.25 | Screening-Technologie von Predictmedix AI unterstützt regulatorische Abkehr der FDA von Tierversuchen als strategisches Asset | 558 | IR-WORLD | TORONTO, 11. April 2025 / IRW-Press / Predictmedix AI Inc. (CSE: PMED) (OTC: PMEDF) (FWB: 3QP) ("Predictmedix" oder das "Unternehmen"), ein führender Anbieter
von KI-gestützten Gesundheits- und... ► Artikel lesen | |
| 19.03.25 | Predictmedix AI Inc.: Predictmedix AI Announces Closing of $405,500 Second Tranche with Strong Participation from German Family Offices | 533 | Business Wire | Predictmedix AI Inc. (CSE: PMED) (OTC: PMEDF) (FRA: 3QP) ("Predictmedix" or the "Company"), a leading provider in AI-powered health screening solutions, is pleased to announce the successful closing... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 37,010 | +1,63 % | SAP, Bayer, Rheinmetall - was ist noch drin? | Für 2026 treffen bei deutschen Aktien hohe Erwartungen auf hohe Bewertungen. Auf fallende Kurse setzen - sprich short gehen - bleibt aber kompliziert in Sachen Timing. Denn wer in den vergangenen 15... ► Artikel lesen | |
| NOVO NORDISK | 44,025 | +0,01 % | Novo Nordisk schon vor Weihnachten reich beschenkt: Explodiert die Aktie jetzt? | Das Börsenjahr 2025 verlief für die Aktie des dänischen Pharmakonzerns Novo Nordisk sehr enttäuschend. Bislang musste man sich schon sehr bemühen, um den letzten Monaten etwas Positives abzugewinnen.... ► Artikel lesen | |
| PFIZER | 21,255 | -0,12 % | Should You Buy Pfizer While It's Under $30? | ||
| ABBVIE | 196,60 | +0,10 % | BofA Cuts AbbVie (ABBV) Target While Maintaining Neutral View | ||
| ELI LILLY | 916,90 | -0,10 % | Große Hoffnung bei Novo Nordisk, Eli Lilly bleibt unbeeindruckt, Evotec klebt im Kurskeller fest und Bayer bricht aus | Nicht erst seit Corona genießen Biotech-Aktien an der Börse viel Aufsehen. Der Sektor fasziniert mit oftmals enormen Chancen, begleitet von einem kaum zu kalkulierenden Risiko. Die Blicke richten sich... ► Artikel lesen | |
| ASSEMBLY BIOSCIENCES | 27,500 | -1,08 % | Gilead Exercises Option To License Assembly Bio's Helicase-Primase Inhibitor Programs | FOSTER CITY (dpa-AFX) - Gilead Sciences (GILD) and Assembly Biosciences (ASMB) announced Gilead has exercised its combined option to exclusively license Assembly Bio's herpes simplex virus helicase-primase... ► Artikel lesen | |
| HARROW | 49,000 | 0,00 % | Harrow, Inc.: Harrow Health, Inc. Announces Closing of Acquisition of Melt Pharmaceuticals | NASHVILLE, Tenn., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has completed the... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 6,450 | +1,10 % | Aquestive Therapeutics, Inc.: Aquestive Therapeutics Broadens Patent Estate for Anaphylm | New patents extend protection for Anaphylm into 2037Anaphylm (dibutepinephrine) Sublingual Film, if approved by the FDA, will be the first and only oral medication for the rescue treatment of severe... ► Artikel lesen | |
| LB PHARMACEUTICALS | 22,250 | +3,49 % | LB Pharmaceuticals Inc: LB Pharmaceuticals Appoints Kaya Pai Panandiker as Chief Commercial Officer | NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc ("LB Pharmaceuticals" or the "Company") (Nasdaq: LBRX), a clinical-stage biopharmaceutical company developing novel therapies for... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 16,910 | +0,71 % | Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution) | - NDA assigned a Target Action Date of February 25, 2026 -- Product has patent protection through 2044 - DEER PARK, Ill., July 08, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the... ► Artikel lesen | |
| BRIGHT MINDS BIOSCIENCES | 78,26 | +3,18 % | H.C. Wainwright reiterates Buy rating on Bright Minds stock with $115 target | ||
| MILESTONE PHARMACEUTICALS | 2,020 | 0,00 % | Milestone Pharmaceuticals Inc.: Milestone Receives FDA Approval of CARDAMYST (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) | First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly resolve episodes of PSVT and restore sinus rhythmFDA approval in PSVT enables... ► Artikel lesen | |
| LIPOCINE | 8,030 | +22,22 % | Lipocine Inc.: Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone | Second Drug Safety Monitoring Board (DSMB) meeting update planned for mid-January 2026
Topline results on track for the second quarter of 2026
SALT LAKE CITY... ► Artikel lesen | |
| INTERCURE | 0,910 | -8,36 % | Intercure Ltd. - 6-K, Report of foreign issuer | ||
| INHIBIKASE THERAPEUTICS | 2,050 | +4,06 % | Jefferies reiterates Buy rating on Inhibikase stock, citing faster FDA path |